Abstract

Since the last CCSG renewal, Development Funds have supported 1) the recruitment of ten outstanding early career investigators, 2) development of two new shared resources and implementation of eight new services in existing shared resources, and 3) partial funding for fourteen MD Anderson Multidisciplinary Research Program (MRP) awards. The $500,000 of CCSG support for faculty recruitment has leveraged over $5.0M in MD Anderson start-up packages and more than $29.6M in new extramural grants. MRP awards provide seed funding of $250,000 over 3 years for groups of three or more center members to support planning and development of P01, SPORE, and CPRIT multi-investigator grant applications. Since the inception of the program in 1997, MD Anderson has invested $11.2M in MRP grants. These awards have been associated with external peer-reviewed funding of more than $157M, representing a 14.1-fold return on investment. During the present grant cycle, 17 proposals have been supported with $625,000 from CCSG Development Funds matched approximately 5:1 with institutional funds. This investment of CCSG support has leveraged $18.6M in extramural funding to date, with $8.8M from Multi-PI awards and $9.8M from individual investigator awards that resulted from projects supported as part of an MRP. Development Funds supported establishing the Functional Genomics Core (FGC) and the Assessment, Intervention and Measurement (AIM) core. In the current CCSG application, Development Funds are requested to continue support for faculty recruitment and fund additional MRP awards. Support is also requested for four developing shared resources: the Oncology Research and Immuno-Monitoring Core (ORION), the Microbiome Core Facility, the Shared Decision Making (SDM) Core, and the Metabolomics Core. Development Funds to provide support for establishing new methods and implementing new technologies within the shared resources and to fund collaborative pilot projects within and between programs are also proposed.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997888
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Taylor, Alison M; Shih, Juliann; Ha, Gavin et al. (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33:676-689.e3
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Jabbour, Elias; DerSarkissian, Maral; Duh, Mei Sheng et al. (2018) Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18:257-265
Pataer, Apar; Shao, Ruping; Correa, Arlene M et al. (2018) Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med 7:2405-2414
Short, Nicholas J; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59:813-820
Shank, Brandon R; Deaver, Melissa; Baker, Angela et al. (2018) Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients. J Oncol Pharm Pract 24:365-370
Keung, Emily Z; Chiang, Yi-Ju; Voss, Rachel K et al. (2018) Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44:170-177
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Lu, Zhongming; Sturgis, Erich M; Zhu, Lijun et al. (2018) Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 57:361-369
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103

Showing the most recent 10 out of 12418 publications